Gray Mary Ann

DirectorRAPT Therapeutics, Inc. (RAPT) · full profile →Form 4 · filed Mar 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
1 non-derivative · 13 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2026Tender(U)5K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 3, 2026Disposed to issuer(D)4780
Mar 3, 2026Disposed to issuer(D)32K0
Mar 3, 2026Disposed to issuer(D)8K0
Mar 3, 2026Disposed to issuer(D)5K0
Mar 3, 2026Disposed to issuer(D)1K0
Mar 3, 2026Disposed to issuer(D)2K0
Mar 3, 2026Disposed to issuer(D)5600
Mar 3, 2026Disposed to issuer(D)1K0
Mar 3, 2026Disposed to issuer(D)4840
Mar 3, 2026Disposed to issuer(D)9380
Mar 3, 2026Disposed to issuer(D)3K0
Mar 3, 2026Disposed to issuer(D)4980
Mar 3, 2026Disposed to issuer(D)9380

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001261974-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly: